Statistik Asas
| CIK | 1530766 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioSig Technologies, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
THIRD AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN Exhibit 10.1 THIRD AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN This THIRD AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN (this “Amendment”), effective as of September 5, 2025, is made and entered into by BioSig Technologies, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not oth |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| September 5, 2025 |
Exhibit 3.1 NINTH CERTIFICATE OF AMENDMENT NINTH CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOSIG TECHNOLOGIES, INC. BioSig Technologies, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware hereby certifies as follows: 1. The name of the Corporation is BioSig Technologies, Inc. The Corporation’s original |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 3) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNO |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commissi |
|
| August 15, 2025 |
Exhibit 99.3 Biosig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No Warrants LOS ANGELES, USA - August 15, 2025 — BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), a gold tokeniza |
|
| August 15, 2025 |
Form of Secured Convertible Debenture Exhibit 10.8 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX |
|
| August 15, 2025 |
BioSig Technologies Inc. Announces Proposed Public Offering Exhibit 99.1 BioSig Technologies Inc. Announces Proposed Public Offering Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (“BioSig” or the “Company”) which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM) today announced its intention to offer shares of common stock (or pre-funded warrants in lieu thereof) through an underwritten public offe |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| August 15, 2025 |
Exhibit 1.1 Certain personally identifiable information has been omitted from this exhibit pursuant to item 601(a)(6) of Regulation S-K. [***] indicates that information has been redacted. 3,852,149 Shares BIOSIG TECHNOLOGIES, INC. Common Stock, $0.001 par value per share UNDERWRITING AGREEMENT August 13, 2025 Clear Street LLC Needham & Company, LLC As Representatives of the several Underwriters C |
|
| August 15, 2025 |
BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering Exhibit 99.2 BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock a |
|
| August 14, 2025 |
BioSig Technologies, Inc. 3,852,149 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-276298 Prospectus Supplement (To Prospectus dated December 17, 2024) BioSig Technologies, Inc. 3,852,149 Shares of Common Stock We are offering 3,852,149 shares of our common stock, par value $0.001 per share. Our common stock is traded on the Nasdaq Capital Market under the symbol “BSGM.” On August 13, 2025, the last reported sale price of our |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commissi |
|
| August 13, 2025 |
Exhibit 10.1 AMENDMENT NO. 1 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT This AMENDMENT NO. 1 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT (this “Amendment”) is made and entered into as of August 13, 2025, by and between BIOSIG TECHNOLOGIES, INC., a company incorporated under the laws of the State of Delaware, with principal executive offices located at 12424 Wilshire Blvd. Suite 74 |
|
| August 13, 2025 |
Subject to Completion, dated August 13, 2025 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 21, 2025 |
Financial Statements For the period ended December 31, 2024 Expressed in Canadian Dollars Exhibit 99.2 Financial Statements For the period ended December 31, 2024 Expressed in Canadian Dollars PAGE REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 3 FINANCIAL STATEMENTS Balance Sheet 4 Statement of Loss and Comprehensive Loss 5 Statement of Changes in Stockholders’ Equity 6 Statement of Cash Flows 7 Notes to the Financial Statements 8 2 Report of Independent Registered Public Acc |
|
| July 21, 2025 |
INFORMATION ABOUT STREAMEX AND THE SHARE EXCHANGE Exhibit 99.1 INFORMATION ABOUT STREAMEX AND THE SHARE EXCHANGE The below is an overview of Streamex’s business and certain other information about Streamex that may be relevant to investors. For purposes of this section the words “we,” “our,” “us,” “Streamex” and the “Company” refers to Streamex. Overview Streamex Exchange Corporation (the “Company” or “Streamex”) was incorporated on April 5, 2024 |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2025 March 31, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdic |
|
| July 21, 2025 |
Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The following unaudited pro forma combined financial information has been prepared in accordance with Article 11 of Regulation S-X under the Securities Act of 1933, as amended and presents the pro forma effects of the acquisition (such transaction, the “Acquisition”) by BioSig Technologies, Inc., a Delaware corporation (“BioSig” or th |
|
| July 9, 2025 |
Exhibit 10.1 SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT THIS SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT (this “Agreement”), dated as of July 7, 2025, is between BIOSIG TECHNOLOGIES, INC., a company incorporated under the laws of the State of Delaware, with principal executive offices located at 12424 Wilshire Blvd. Suite 745, Los Angeles, CA 90025 (the “Company”), and YA II PN, Ltd. (t |
|
| July 9, 2025 |
Exhibit 99.1 BioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1,100,000,000 ($1.1B USD) in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Commodities Markets ● BioSig Technologies, Inc. (Nasdaq: BSGM), which recently merged with Streamex Exchange Corporation (“Streamex”) to beco |
|
| July 9, 2025 |
Exhibit 10.2 FORM OF LOCK-UP LETTER AGREEMENT [], 2025 CANTOR FITZGERALD & CO. 110 East 59th Street, 6th Floor New York, NY 10022 CLEAR STREET LLC 4 World Trade Center, Floor 45 New York, NY 10007 RE: PROPOSED PRIVATE PLACEMENT BY BIOSIG TECHNOLOGIES, INC. Ladies and Gentlemen: The undersigned understands that BioSig Technologies, Inc., a Delaware corporation (the “Company”), is entering into a Se |
|
| July 9, 2025 |
Standby Equity Purchase Agreement, dated as of July 7, 2025, between Company and YA II PN, Ltd. Exhibit 10.3 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of July 7, 2025, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and BioSig Technologies, Inc., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein indivi |
|
| July 9, 2025 |
Form of Registration Rights Agreement, by and between Company and YA II PN, Ltd. Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July [ ], 2025, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and BIOSIG TECHNOLOGIES, INC., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein individuall |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commission |
|
| May 30, 2025 |
Exhibit 10.2 FIRST AMENDMENT TO SHARE PURCHASE AGREEMENT This First Amendment (this “First Amendment”) to the Share Purchase Agreement (as defined below) is made and entered into as of May 27, 2025, by BIOSIG TECHNOLOGIES, INC., a Delaware corporation (“Parent”), BST SUB ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly-owned subsidiary o |
|
| May 30, 2025 |
Exhibit 99.1 Streamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq May 28, 2025 Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig”) and Streamex Exchange Corporation (“Streamex”), collectively refe |
|
| May 30, 2025 |
Exhibit 10.1 FORM OF FINDER AGREEMENT This FINDER AGREEMENT (this “Agreement”) is made and entered into as of this [●] day of May, 2025, by and among [●] (“Finder”), Streamex Exchange Corp. (the “Company”) and BioSig Technologies, Inc. (the “Target Company” and together with Finder and the Company, the “Parties”). R E C I T A L S A. The Company desires an introduction to the management of the Targ |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commission |
|
| May 27, 2025 |
Exhibit 10.5 , 2025 Re: Letter Agreement - Right to Place This letter agreement (“Letter Agreement”) sets forth the terms of the mutual understanding and agreement of BioSig Technologies, Inc. (“BSGM”) and Anthony Amato (“Amato”) with regard to BSGM’s Right to Place (as defined below). In consideration of the foregoing and for other good and valuable consideration, including the amendment of that |
|
| May 27, 2025 |
Exhibit 10.3 SUPPORT AGREEMENT among BIOSIG TECHNOLOGIES, INC. and BST SUB ULC AND 1540875 B.C. LTD. DATED as of [], 2025 Table of Contents Article 1 DEFINITIONS AND INTERPRETATION 3 1.1 Definitions 3 1.2 Interpretation Not Affected by Headings. 4 1.3 Number and Gender. 4 1.4 Date of any Action. 4 1.5 Statutes. 4 Article 2 COVENANTS OF PARENT AND EXCHANGECO 5 2.1 Covenants Regarding Exchangeable S |
|
| May 27, 2025 |
Form of Certificate of Designation of Special Voting Stock of BioSig Technologies, Inc. Exhibit 3.1 BIOSIG TECHNOLOGIES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SPECIAL VOTING PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of BioSig Technologies, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Board o |
|
| May 27, 2025 |
Form of Exchange Rights Agreement Exhibit 10.2 EXCHANGE RIGHTS AGREEMENT BY AND AMONG BIOSIG TECHNOLOGIES, INC. BST SUB ULC 1540875 B.C. LTD. AND 1540873 B.C. LTD. DATED AS OF [], 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS AND INTERPRETATION 5 1.1 Definitions 5 1.2 Interpretation Not Affected by Headings 8 1.3 Number, Gender, etc. 8 1.4 Date for any Action 8 1.5 Currency 8 1.6 Statutes 8 1.7 Exhibits 9 ARTICLE 2 9 TRUST 9 2.1 Es |
|
| May 27, 2025 |
Exhibit 10.1 FORM OF PARENT STOCKHOLDER VOTING AGREEMENT BIOSIG TECHNOLOGIES, INC. VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”), dated as of [], 2025, is made by and among BioSig Technologies, Inc., a Delaware corporation (“Parent”), Streamex Exchange Corporation, a corporation organized under the laws of the Province of British Columbia (the “Company”), and the undersigned holder (“S |
|
| May 27, 2025 |
Exhibit 99.1 BioSig Technologies, Inc. Signs Definitive Share Exchange Agreement with Streamex Exchange Corp. to Launch First-Mover Real-World Asset (RWA) Tokenization Company Bringing Commodity Markets On-Chain. May 23, 2025 Los Angeles, CA and Vancouver, BC, May 23, 2025 (GLOBE NEWSWIRE) – BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company, today a |
|
| May 27, 2025 |
Exhibit 2.1 SHARE PURCHASE AGREEMENT by and among BIOSIG TECHNOLOGIES, INC., a Delaware corporation; BST SUB ULC, a British Columbia, Canada unlimited liability company; 1540875 B.C. LTD., a British Columbia, Canada corporation; STREAMEX EXCHANGE CORPORATION, a British Columbia, Canada corporation; each shareholder of STREAMEX EXCHANGE CORPORATION; and 1540873 B.C. LTD., as Trustee of the trust fo |
|
| May 27, 2025 |
Form of First Amendment to the Executive Employment Agreement Exhibit 10.4 First AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This First AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), entered into as of the Effective Time (as defined below), by and between Anthony Amato (“Executive”) and BioSig Technologies Inc., a Delaware corporation (the “Company”), for the purpose of amending that certain Executive Employment Agreement, dated as of August |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commission |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHN |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of in |
|
| May 5, 2025 |
Figure 1: The Streamex Ecosystem Figure 2: The Streamex Platform Exhibit 99.2 BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives Los Angeles, CA, May 5, 2025 (GLOBE NEWSWIRE) – BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company is pleased to announce it has entered into a Letter of Intent (“LOI”) to en |
|
| May 5, 2025 |
Exhibit 99.1 CONFIDENTIAL Letter of Intent May 5, 2025 BioSig Technologies, Inc. Anthony Amato Chief Executive Officer 12424 Wilshire Blvd., Ste. 745 Los Angeles, CA 90025 RE: Proposed Merger Transaction between BioSig Technologies, Inc. and Streamex Exchange Corporation Dear Mr. Amato, This Letter of Intent (this “LOI”) summarizes the principal terms relating to a proposed merger or other busines |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commissio |
|
| April 30, 2025 |
Letter from Marcum LLP dated April 30, 2025 Exhibit 16 April 30, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by BioSig Technologies, Inc. under Item 4.01 of its Form 8-K dated April 30, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of BioSig Technologies, Inc. cont |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commissio |
|
| April 15, 2025 |
EXHIBIT 31.02 CERTIFICATION I, Ferdinand Groenewald, certify that: 1. I have reviewed this annual report on Form 10-K of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading w |
|
| April 15, 2025 |
EXHIBIT 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of April 14, 2025, BioSig Technologies, Inc., a Delaware corporation (“we,” “our” and the “Company”) has our common stock, par value $0.001 per share registered under Section 12 of the Securities Exchange Act of 1934, as amended. The foregoing description is intended as a summary and i |
|
| April 15, 2025 |
EXHIBIT 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Anthony Amato, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of BioSig Technologies, Inc. on Form 10-K for the fiscal year ended December 31, 202 |
|
| April 15, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commissio |
|
| April 15, 2025 |
EXHIBIT 31.01 CERTIFICATION I, Anthony Amato, certify that: 1. I have reviewed this annual report on Form 10-K of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| April 15, 2025 |
Exhibit 4.42 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 15, 2025 |
Exhibit 19.1 BIOSIG TECHNOLOGIES, INC. Insider Trading COMPLIANCE POLICY BioSig Technologies, Inc. (the “Company”) prohibits: ● insider trading in the Company’s securities (“Securities”)1; and ● the unauthorized disclosure of the Company’s confidential information that might enable others to engage in insider trading in the Securities. The Company adopted this Insider Trading Compliance Policy to |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Or ☐ TRANSITION REPORT UNDER SECTON 13.08 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact |
|
| April 15, 2025 |
EXHIBIT 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Ferdinand Groenewald, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of BioSig Technologies, Inc. on Form 10-K for the fiscal year ended December |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commissio |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission |
|
| March 5, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission |
|
| March 5, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 5, 2025 between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| March 5, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commis |
|
| March 3, 2025 |
Exhibit 10.1 EQUITY SUBSCRIPTION AGREEMENT THIS EQUITY SUBSCRIPTION AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of February 28, 2025, is made by and between Lind Global Fund III, LP, a Delaware limited partnership (the “Investor”), and BioSig Technologies, Inc., a Delaware corporation (the “Company”). The Investor and the Compan |
|
| January 13, 2025 |
As filed with the Securities and Exchange Commission on January 13, 2025 As filed with the Securities and Exchange Commission on January 13, 2025 Registration No. |
|
| January 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioSig Technologies, Inc. |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| December 31, 2024 |
Exhibit 10.1 SECOND AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN This SECOND AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN (this “Amendment”), effective as of December 31, 2024, is made and entered into by BioSig Technologies, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not o |
|
| December 18, 2024 |
BioSig Technologies, Inc. Up to $8,500,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-276298 Prospectus Supplement (To Prospectus Dated December 17, 2024) BioSig Technologies, Inc. Up to $8,500,000 of Common Stock We have entered into an At The Market Offering Agreement, dated December 18, 2024 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC, as sales agent or principal (“Wainwright” or the “sales agent”) relating to th |
|
| December 18, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commis |
|
| December 18, 2024 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT December 18, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, New York 10022 Ladies and Gentlemen: BioSig Technologies, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, |
|
| December 13, 2024 |
BioSig Technologies, Inc. 12424 Wilshire Blvd, Suite 745 Los Angeles, California 90025 BioSig Technologies, Inc. 12424 Wilshire Blvd, Suite 745 Los Angeles, California 90025 December 13, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attention: Robert Augustin Re: BioSig Technologies, Inc. Registration Statement on Form S-3 File No. 333-276298 (the “Registration Statement”) Request for Acceleration Ladies and Gentlemen: |
|
| December 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BioSig Technologies, Inc. |
|
| December 9, 2024 |
As filed with the U.S. Securities and Exchange Commission on December 9, 2024 As filed with the U.S. Securities and Exchange Commission on December 9, 2024 Registration No. 333-276298 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdi |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 14, 2024 |
BSGM / BioSig Technologies, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-bsgm093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioSig Technologies, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09073N300 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) C |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG T |
|
| November 13, 2024 |
BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement Exhibit 99.1 BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement Los Angeles, CA, November 13, 2024 —BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced that it has received notice from the Nasdaq Listing Qualifications staff (“Nasdaq”) |
|
| November 13, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employe |
|
| September 13, 2024 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 1st day of August 2024 (the “Effective Date”), by and between BioSig Technologies Inc. (the “Company”), and Anthony Amato (“Executive”). WHEREAS, the Company wishes to continually employ Executive as its Chief Executive Officer (“CEO”); and WH |
|
| September 13, 2024 |
Exhibit 10.3 BIOSIG TECHNOLOGIES, INC. FORM OF STOCK OPTION AGREEMENT I. NOTICE OF STOCK OPTION GRANT Name: The undersigned Optionee has been granted this Option (defined below) to purchase common stock (“Common Stock”) of BioSig Technologies, a Delaware corporation, or any successor thereto (the “Company”), subject to the terms and conditions of this BioSig Technologies, Inc. Stock Option Agreeme |
|
| September 13, 2024 |
Form of Restricted Stock Award Agreement Exhibit 10.2 BIOSIG TECHNOLOGIES, INC. FORM OF RESTRICTED STOCK AWARD AGREEMENT 1. Grant of Award. Pursuant to the terms of this Restricted Stock Award Agreement (this “Agreement”) and in exchange for services rendered to BioSig Technologies, Inc., a Delaware corporation (the “Company”), the Company hereby grants to (the “Grantee”) an award of shares of restricted stock (the “Awarded Shares”). The |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNO |
|
| August 14, 2024 |
EXHIBIT 31.2 CERTIFICATION I, Ferdinand Groenewald, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| August 14, 2024 |
EXHIBIT 32.1 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Anthony Amato, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for the fis |
|
| August 14, 2024 |
EXHIBIT 31.1 CERTIFICATION I, Anthony Amato, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| July 31, 2024 |
PROSPECTUS BioSig Technologies, Inc. 1,680,631 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-280525 PROSPECTUS BioSig Technologies, Inc. 1,680,631 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 1,680,631 shares of our common stock, par value $0.001 per share, issuable upon the exercise of outstanding warrants issued on May 30, 2024, pursuant t |
|
| July 29, 2024 |
July 29, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. |
|
| July 24, 2024 |
As filed with the Securities and Exchange Commission on July 23, 2024 As filed with the Securities and Exchange Commission on July 23, 2024 Registration No. |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission |
|
| July 24, 2024 |
Engagement Agreement between BioSig Technologies, Inc. and H.C. Wainwright, dated May 29, 2024 Exhibit 10.26 Execution Version May 29, 2024 STRICTLY CONFIDENTIAL BioSig Technologies, Inc. 55 Greens Farms Road, 1st Floor Westport, Connecticut 06880 Attn: Anthony Amato, Principal Executive Officer Dear Mr. Amato: This letter agreement (this “Agreement”) constitutes the agreement between BioSig Technologies, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright sh |
|
| July 23, 2024 |
BioSig Technologies, Inc. 12424 Wilshire Blvd Suite 745 Los Angeles, CA 90025 BioSig Technologies, Inc. 12424 Wilshire Blvd Suite 745 Los Angeles, CA 90025 July 23, 2024 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Aja Eiden Katherine Bagley Re: BioSig Technologies, Inc. Registration Statement on Form S-1 Filed June 27, 2024 File |
|
| June 27, 2024 |
As filed with the Securities and Exchange Commission on June 27, 2024 As filed with the Securities and Exchange Commission on June 27, 2024 Registration No. |
|
| June 27, 2024 |
Calculation of Filing Fees Table EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) BioSig Technologies, Inc. |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission |
|
| June 11, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of i |
|
| June 10, 2024 |
Exhibit 99.1 BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer WESTPORT, CT, June 10, 2024 —BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or “the Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of |
|
| May 30, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 30, 2024 |
1,570,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-251859 PROSPECTUS SUPPLEMENT (To the Prospectus Dated January 12, 2021) 1,570,683 Shares of Common Stock We are offering 1,570,683 shares of our common stock, $0.001 par value per share, at a purchase price of $1.91 per share of common stock (the “common stock”) directly to institutional investors pursuant to this prospectus supplement and the |
|
| May 30, 2024 |
BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into definiti |
|
| May 30, 2024 |
Exhibit 4.1 EXHIBIT A-1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of i |
|
| May 30, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 29, 2024, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| May 30, 2024 |
Exhibit 99.2 BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Westport, CT, May 30, 2024 — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of i |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of i |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHN |
|
| May 20, 2024 |
EXHIBIT 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Anthony Amato, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for the fi |
|
| May 20, 2024 |
EXHIBIT 31.01 CERTIFICATION I, Anthony Amato, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| May 20, 2024 |
EXHIBIT 31.02 CERTIFICATION I, Frederick D. Hrkac, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| May 16, 2024 |
OMB APPROVAL UNITED STATES OMB Number: 3235-0058 SECURITIES AND EXCHANGE COMMISSION Expires: April 30, 2025 Washington, D. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of in |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of in |
|
| May 7, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 1, 2024, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| May 7, 2024 |
Exhibit 99.1 BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent WESTPORT, CT, May 03, 2024 —BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or “the Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of |
|
| May 3, 2024 |
Exhibit 99.1 BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately Mr. Amato will also serve on the Company’s Board of Directors WESTPORT, CT, April 30, 2024 —BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or “the Company”), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visual |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of in |
|
| April 16, 2024 |
EXHIBIT 31.01 CERTIFICATION I, Frederick D. Hrkac, certify that: 1. I have reviewed this annual report on Form 10-K of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wit |
|
| April 16, 2024 |
EXHIBIT 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Frederick D. Hrkac, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of BioSig Technologies, Inc. on Form 10-K for the f |
|
| April 16, 2024 |
EXHIBIT 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of April 15, 2024, BioSig Technologies, Inc., a Delaware corporation (“we,” “our” and the “Company”) has our common stock, par value $0.001 per share registered under Section 12 of the Securities Exchange Act of 1934, as amended. The foregoing description is intended as a summary and i |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 Or ☐ TRANSITION REPORT UNDER SECTON 13.08 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact |
|
| April 16, 2024 |
Compensation Recovery Policy adopted November 6, 2023 EXHIBIT 97 BIOSIG TECHNOLOGIES, INC. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) of BioSig Technologies, Inc. (the “Company”) is hereby adopted as of November 6, 2023 in compliance with Rule 5608 of the Nasdaq Rules. Certain terms used herein shall have the meanings set forth in “Section 3. Definitions” below. Section 1. Recovery Requirement Subject to Section 4 |
|
| April 2, 2024 |
OMB APPROVAL UNITED STATES OMB Number: 3235-0058 SECURITIES AND EXCHANGE COMMISSION Expires: April 30, 2025 Washington, D. |
|
| March 18, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of |
|
| March 12, 2024 |
Exhibit 4.1 THE SECURITY REPRESENTED HEREBY HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS SECURITY MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IN COMPLIANCE WITH RULE 144 UNDER THE SECURITIES ACT, IF AVAILABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (C) PURSUANT TO AN EFFECTI |
|
| March 12, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| February 14, 2024 |
BSGM / BioSig Technologies, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 6, 2024 |
BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases Exhibit 99.1 BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases ● Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%. Westport, CT, Feb. 06, 2024 (GLOBE NEWSWIRE) – BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committ |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of inc |
|
| February 1, 2024 |
Consulting Agreement, dated January 31, 2024 Exhibit 10.1 biosig technologies, Inc. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into (the “Effective Date”) by and between BioSig Technologies, Inc., a Delaware corporation with its principal place of business at 55 Greens Farms Rd 1st Floor Westport, CT 06880 (the “Company”), and , with a principal place of business/residence at (“Consultant”) (each he |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| January 31, 2024 |
Exhibit 99.1 BioSig Announces Reverse Stock Split ● Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024 Westport, CT, January 31, 2024 (GLOBE NEWSWIRE) - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| January 31, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOSIG TECHNOLOGIES, INC. BioSig Technologies, Inc., (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The original Certificate of Incorporation of this Corporation was filed with the Secretary |
|
| January 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss |
|
| January 30, 2024 |
BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy Exhibit 99.1 BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy ● Cost Savings Targeted to Reduce Cash Burn by 50% ● Core Strategy Shifts to Business Development and Distribution Partnerships Westport, CT, January 30, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to d |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss |
|
| January 12, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 12, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 12, 2024, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commissi |
|
| January 5, 2024 |
As filed with the U.S. Securities and Exchange Commission on January 5, 2024 As filed with the U.S. Securities and Exchange Commission on January 5, 2024 Registration No. 333-276298 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdic |
|
| December 29, 2023 |
BioSig Technologies, Inc. 55 Greens Farms Road, 1st Floor Westport, CT 06880 BioSig Technologies, Inc. 55 Greens Farms Road, 1st Floor Westport, CT 06880 December 29, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: BioSig Technologies, Inc. Registration Statement on Form S-3, filed on December 28, 2023 File No. 333-276298 Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-3 (File |
|
| December 28, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| December 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BioSig Technologies, Inc. |
|
| December 28, 2023 |
Form of Consultant Warrant dated November 18, 2022 Exhibit 4.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 28, 2023 |
As filed with the U.S. Securities and Exchange Commission on December 28, 2023 As filed with the U.S. Securities and Exchange Commission on December 28, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdiction of incorporation or organization |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| December 18, 2023 |
Exhibit 10.1 FIRST AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN This FIRST AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN (this “Amendment”), effective as of December 18, 2023, is made and entered into by BioSig Technologies, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not oth |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| December 6, 2023 |
LETTER TO SHAREHOLDERS December 2023 Exhibit 99.1 LETTER TO SHAREHOLDERS December 2023 Dear fellow shareholders, As we approach the end of 2023, I want to share with you BioSig’s important achievements of the past 12 months, showcase our strengths and strategies, address our challenges, and offer insights about the year ahead. This year, we completed BioSig’s business transition from a traditional medtech sales model with a technolog |
|
| December 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 14, 2023 |
EXHIBIT 31.01 CERTIFICATION I, Kenneth L. Londoner, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG T |
|
| November 14, 2023 |
EXHIBIT 31.02 CERTIFICATION I, Steven J. Buhaly, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| November 14, 2023 |
EXHIBIT 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Kenneth L. Londoner, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for |
|
| November 13, 2023 |
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Westport, CT, Nov. 13, 2023 — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registe |
|
| November 13, 2023 |
Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BioSig Technologies, Inc. Warrant Shares: Issue Date: November 13, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| November 13, 2023 |
Exhibit 4.2 SERIES B COMMON STOCK PURCHASE WARRANT BioSig Technologies, Inc. Warrant Shares: Issue Date: November 13, 2023 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the earlier of |
|
| November 13, 2023 |
Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT BioSig Technologies, Inc. Warrant Shares: Issue Date: November 13, 2023 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the earlier of |
|
| November 13, 2023 |
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Westport, CT, Nov. 9, 2023 — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into a definitive agreement |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| November 13, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-251859 PROSPECTUS SUPPLEMENT (To the Prospectus Dated January 12, 2021) 6,996,922 Shares of Common Stock Series A Warrants to Purchase up to 6,996,922 Shares of Common Stock Series B Warrants to Purchase up to 6,996,922 Shares of Common Stock Placement Agent Warrants to Purchase up to 489,785 Shares of Common Stock 14,483,629 Shares of Common S |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer |
|
| November 13, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 8, 2023, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss |
|
| November 8, 2023 |
Exhibit 3.1 Amendment No. 3 to Amended and Restated Bylaws of BioSig Technologies, Inc. Pursuant to Article VI of the Certificate of Incorporation, as amended, of BioSig Technologies, Inc., a Delaware corporation (the “Corporation”), Article X of the Amended and Restated Bylaws (as amended heretofore, the “Bylaws”) of the Corporation, and Section 109 of the General Corporation Law of the State of |
|
| November 7, 2023 |
BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP Exhibit 99.1 BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP 32-year career in medical device and electrophysiology business expansion for industry bellwethers; led multiple company exits including a $1B sale in 2018 Part of leadership team that grew Johnson & Johnson’s original cardiology/electrophysiology business from $22M to $500M in 7 years Westport, CT, November 7, 2023 |
|
| November 7, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) ( |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) ( |
|
| November 2, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) ( |
|
| November 2, 2023 |
Exhibit 99.1 BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care PURE EP™ subscriber community now includes two of top three U.S. health systems in cardiology: Mayo Clinic-Phoenix and Cleveland Clinic Westport, CT, November 2, 2023 (GLOBE NEWSWIRE) - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company c |
|
| November 1, 2023 |
Exhibit 99.1 BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI ● IP portfolio includes U.S. and worldwide utility and design patents and pending applications in the U.S., Europe, and Asia-Pacific Westport, CT, November 1, 2023 (GLOBE NEWSWIRE) - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical techno |
|
| November 1, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) ( |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 16, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) ( |
|
| October 16, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 16, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 12, 2023, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| September 27, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 27, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) |
|
| September 27, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 21, 2023, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and con |
|
| September 15, 2023 |
Exhibit 1.1 BIOSIG TECHNOLOGIES, INC. Common Stock (par value $0.001 per share) At-The-Market Issuance Sales Agreement September 15, 2023 Ascendiant Capital Markets, LLC 110 Front Street, Suite 300 Jupiter, FL 33477 Ladies and Gentlemen: BioSig Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Ascendiant Capital Markets, LLC (the “Agent”), a |
|
| September 15, 2023 |
Up to $30,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-251859 PROSPECTUS SUPPLEMENT (To the Prospectus Dated January 12, 2021) Up to $30,000,000 Common Stock We have entered into an At-The-Market Issuance Sales Agreement, or the sales agreement, with Ascendiant Capital Markets, LLC, or Ascendiant, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplem |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) |
|
| September 12, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 12, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 12, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) |
|
| September 12, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 12, 2023, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and con |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (I |
|
| August 24, 2023 |
Exhibit 99.1 BioSig Technologies, Inc. www.biosig.com 1 (870) SIGNALS [email protected] 55 Greens Farms Rd, FL 1 Westport, CT 06880 BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (I |
|
| August 23, 2023 |
Exhibit 99.1 BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations Cleveland Clinic, the #1 heart center in the Nation, signs on as first subscriber to receive latest software advancements in intracardiac signal visualization Westport, CT, August 23, 2023 (GLOBE NEWSWIRE) - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or th |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (I |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (I |
|
| August 22, 2023 |
Exhibit 99.1 BioSig's PURE EP™ Platform Debuts New Automated Features in First Patient Cases Latest Software Release Supports Electrophysiologists with Visualizing Heart Patterns Difficult to Recognize with the Naked Eye Westport, CT, Aug. 22, 2023 (GLOBE NEWSWIRE) - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy |
|
| August 18, 2023 |
Up to $30,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-251859 PROSPECTUS SUPPLEMENT (To the Prospectus Dated January 12, 2021) Up to $30,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or the sales agreement, with Cantor Fitzgerald & Co., or Cantor, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (I |
|
| August 18, 2023 |
Exhibit 1.1 BIOSIG TECHNOLOGIES, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement August 18, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: BioSig Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. |
|
| August 14, 2023 |
EXHIBIT 31.01 CERTIFICATION I, Kenneth L. Londoner, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| August 14, 2023 |
EXHIBIT 31.02 CERTIFICATION I, Steven J. Buhaly, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNO |
|
| August 14, 2023 |
EXHIBIT 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Kenneth L. Londoner, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for |
|
| July 31, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 31, 2023, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (IRS |
|
| July 31, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 31, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (IRS |
|
| July 21, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”) is dated as of July 19, 2023 by and among BioSig AI Sciences, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto and such purchasers’ respective successors and assigns (individually, a “Purchaser” and collectively, the “Purchasers”). The par |
|
| July 20, 2023 |
Exhibit 99.1 BioSig AI Sciences Selected for NVIDIA Inception Partnership Program to Support R&D Collaboration on AI Medical Device Platform for Hospitals WESTPORT, CONN., July 20, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today anno |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (IRS |
|
| June 30, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”) is dated as of June 30, 2023 by and among BioSig AI Sciences, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto and such purchasers’ respective successors and assigns (individually, a “Purchaser” and collectively, the “Purchasers”). The par |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (IRS |
|
| June 27, 2023 |
Exhibit 99.1 BioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare Westport, CT, June 27, 2023 - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it is advancing the research and development |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (IRS |
|
| May 22, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 16, 2023, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (IRS |
|
| May 22, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 22, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission File Number) (IRS |
|
| May 19, 2023 |
Exhibit 99.1 New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias Data from three abstracts highlight the potential of an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI) Preservation of raw unipolar signal using BioSig’s PURE EP™ platform guidance enabled real-time tissue-specific feedb |
|
| May 15, 2023 |
EXHIBIT 31.01 CERTIFICATION I, Kenneth L. Londoner, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| May 15, 2023 |
EXHIBIT 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Kenneth L. Londoner, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHN |
